Abstract
Keywords
Introduction
Diabetic peripheral neuropathy (DPN) is one of the most common, expensive, and disabling complications of diabetes (1). Previous studies have reported a worldwide prevalence of 22.7% to 54% for it (2). Painful form of this complication is very uncomfortable for patients and despite recent improvements in its treatment, the pain is often inadequately controlled (3). A wide variety of oral medications have been shown to considerably reduce neuropathic pain compared with placebo in randomized controlled trials (4). Because of less systemic side effects, use of topical medications in this field is more acceptable. The final goal of development of topical compounds is the better compliance to medical treatment, by providing efficient pain relief with less central nervous system effects and minimal drug regimen burden (5). Efficacy of topical capsaicin formulations those act by the reduction of substance P content in skin have demonstrated in controlled clinical trials (6-8). Amitriptyline is a tricyclic antidepressant that acts centrally by inhibiting neuronal reuptake of norepinephrine and serotonin and is used effectively in many chronic neuropathic pain conditions (9-11). But its adverse effects such as sedation, postural hypotension, and anticholinergic effects, in oral administration have limited titration to higher doses needed to achieve adequate analgesia (12). Topical form of this drug is used in some studies for the treatment of neuropathic pain (12-14). Given the greater tendency to use of local medications in this area, this study aimed to compare the effect of amitriptyline and capsaicin cream in relieving pain associated with DPN.
Experimental
Study participants
Patients with type 2 diabetes, aged between 30 and 70 years, who had DPN were considered for the study. Patients with chronic daily pain for more than three months, who had a pain score of at least 4 as assessed by visual analog scale (VAS), were enrolled in the study. Patients with less than one year duration of diabetes, opium or alcohol use, other causes of neuropathy, hepatic or renal failure (serum creatinine > 1.5 mg/dl), clinically significant cardiovascular disease, HA1C ≥ 9%, pregnancy or lactation, ulcer or infection of foot and hypersensitivity to pepper were excluded from the study. Use of any medication for neuropathic pain was discontinued two weeks before enrolling in the study and throughout it, but required therapies including insulin and oral hypoglycemic agents were maintained throughout the study.
Study design and treatment
This study was approved by Hamedan University of Medical Sciences Research Ethics Committee (D/P/16/35/9/1282) and had been registered in IRCT (Registration ID: IRCT201209238308N2). This 12-week, randomized, double-blind, parallel-group and non-inferiority trial was conducted to compare the efficacy and safety of amitriptyline and capsaicin for pain associated with DPN. Laboratory tests, physical examinations, body weight, height, blood pressure and general characteristics including age, duration of diabetes, history of hypertension, pain duration and medications were recorded at the base of the study. PDN was confirmed by NSS (Neuropathy Symptom Score) and NDS (Neuropathy Disability Score) criteria (15, 16). Patients were randomized to amitriptyline or capsaicin group. Randomization was done by permuted-block design that involves randomizing patients in treatment groups in sequential blocks. Patients were then treated under double-blind conditions for up to 3 months. Written informed consent was obtained from each patient prior to enrollment.
The study drugs were amitriptyline 2% cream and capsaicin 0.75% cream in no label laminated tubes containing 100 gram of material. In order to fabricate amitriptyline oil/water cream, both Lipid phase (including isopropyl myristate, Cetyl palmitate, Stearyl alcohol, Cetyl alcohol and Span 60) and aqueous phase (contained of Amitriptyline, Tween 80 and distilled water) were separately heated to 75ºC. After that, the hot water phase was added to the lipid phase under stirring (600 rpm) and cooled down to 25ºC. We used 2% concentration of the amitriptyline cream because a few controlled clinical trials examined previously this concentration and had demonstrated its efficacy and safety (13, 14, 17). Amitriptyline active ingredient was obtained from Iran Daru Pharmaceutical Company (Iran) and capsaicin was provided by Kish Medipharm pharmaceutical Company (Iran). Physicochemical and microbial tests of amitriptyline cream were assessed by ICH methods and USP guidelines. Formulation was kept at 45ºC and 75% humidity for 6 months (accelerated conditions) and during this period, stability data were getting at month 1, 3 and 6. No changing in pH, viscosity, density, formulation color, odor and etc was seen. Also total bacterial count (CFU/g) and total fungi and yeast count (CFU/g) were determined.
Amitriptyline or capsaicin was dispensed to patient according to randomized group assignment. Patients applied either of drugs topically below the ankles on the feet 3 times a day.
The end point of the study was the reduction in the median pain score from baseline, as assessed by the VAS (0-10 points). Evaluations of the patients including assessment of the pain severity, vital signs and examination and questioning regarding the adverse effects were performed at each of the 4-week follow-up visits. Compliance was assessed by direct questioning. The investigator was accessible by telephone to all patients throughout the study.
Statistical analysis
The efficacy analyses were performed on both per protocol analysis and the intention-to-treat (ITT) analysis. ITT population was defined as randomized patients who took at least one dose of medication and provided at least one baseline and one post-baseline efficacy assessment. The efficacy endpoint was the change in mean monthly pain score on the Visual Analogue Scale (VAS). Values are expressed as means ± SD and numbers and percentages. The patient VAS was compared using the Student t test. Cure rates between treatment groups and incidence of adverse events were compared by Chi-Square Test. Repeated measure analysis was performed on VAS change scores (from baseline to week 12). Baseline parameters were compared by the Student t test, Mann-Whitney or Chi-Square tests. Missing data for subjects who terminated early were imputed using multiple imputations by regression method. A P value < 0.05 was considered significant. SPSS (version 20.0) was used to perform analysis.
Results and Discussion
The study was conducted between February 2013 and January 2014. Patients’ demographic and baseline characteristics were comparable between two groups of treatments as presented in Table 1. The flow chart of patient enrollment and disposition is shown in Figure 1.197 eligible
patients of 354 screened patients were enrolled in the study. The ITT population for the efficacy analysis consists of 51 patients receiving amitriptyline and 51 patients receiving capsaicin. 64 patients of a total of 102 completed the study with 62.7% compliance. A total of 38 (37.2%) patients discontinued therapy during the treatment period: 16 (31.3%) taking amitriptyline and 22 (43.1%) taking capsaicin (P = 0.219).
Demographic and baseline characteristics of patients in capsaicin and amitriptyline groups.
| Variable | Capsaicin group | amitriptyline group | P-value |
|---|---|---|---|
| Age, years (SD) | 55.4±10.6 | 57.5±10.8 | 0.314 |
| Gender | |||
| Female, n (%) | 35(68.6) | 34(66.7) | 0.832 |
| Height (cm) | 163.3±7.9 | 162.0±7.4 | 0.644 |
| Weight (kg) | 74.4±11.3 | 72.9±12.9 | 0.524 |
| Body Mass Index (Kg/m2) | 27.5±3.4 | 27.4±4.1 | 0.894 |
| Duration of diabetes (years) | 8.0±5.1 | 9.0±6.7 | 0.864 |
| HbA1C | 7.2±0.89 | 7.5±1.1 | 0.177 |
| Creatinine | 0.9±0.19 | 1.0±0.25 | 0.055 |
| Medication (%) Oral agent | 24(47.1) | 28(54.9) | 0.269 |
| Pain Duration (month) | 19.0±18.3 | 18.9±15.3 | 0.763 |
| Mean basal VAS | 7.4±1.4 | 7.8±1.7 | 0.172 |
Treatment responders (≥ 50% reduction from baseline on the VAS assessment) (18) in the ITT population, at week 12, were 22 (43.1%) and 19 (37.3%) of patients with amitriptyline and capsaicin, respectively (P = 0.545).
Pain in the intention to treat population decreased with time as shown in Figure 2 (p value < 0.001 for both of them). The slope of the pain decline in amitriptyline group (-1.26) was approximately similar to the capsaicin group (-1.13). There was no significant difference between the slopes of VAS decline between the two groups (Δ = 0.13, p = 0.703). Per protocol analysis showed similar results. In logistic regression analysis there was not any relationship between patient’s basic characteristics and response to treatment in amitriptyline and capsaicin groups.
Adverse events were more common in capsaicin group: 13 (25.5%) patients in amitriptyline group and 29 (56.9%) patients in capsaicin group (P = 0.001). Dermatologic complications were the most common reported adverse events. In the amitriptyline group skin dryness and then itching were the most common dermatologic adverse effects (8.8% and 4.4%, respectively). The most common local side effects of capsaicin were itching, blister formation and erythema respectively (20%, 8.5% and 5.7%).
This randomized, double-blind and non-inferiority, 12-week trial demonstrates the comparable efficacy of amitriptyline cream in comparison with capsaicin cream in the management of pain due to peripheral neuropathy in type 2 diabetic patients. In addition to relieving pain, treatment with amitriptyline cream was also associated with less adverse events.
A few studies evaluated the effect of topical amitriptyline in this field. A study by Kopsky described two cases of neuropathic pain of those treated effectively with topical amitriptyline 5% and 10% (19). In a randomized, double-blind and placebo controlled trial, the analgesic effects of 50 mmol/L and 100 mmol/L solutions of amitriptyline those evaluated in 14 healthy volunteers were significantly higher than those of the placebo (20). A cure rate of 43.1% and 25.5% adverse events for amitriptyline cream those were better than capsaicin shows the value of this drug for more research. Inconsistent with results of our study, an open label pilot study that examined the effect of topical amitriptyline, ketamine and a combination of both for neuropathic pain, didn’t show any significant difference from placebo for any treatment (21). Also, a double-blind, randomized, placebo-controlled crossover study that evaluated the efficacy of topical 5% amitriptyline and 5% lidocaine in treating of neuropathic pain failed to show efficacy of topical amitriptyline (12). In general, in our study amitriptyline was well tolerated and safe during this 12-week study. There were more discontinuations due to adverse events in the capsaicin treatment group than in the amitriptyline treatment group. This study compared the efficacy of amitriptyline cream with capsaicin cream, a FDA approved drug, but prolonged therapy and evaluation for a longer duration than 12 weeks can better evaluate the benefits of this drug. Strength of the current study includes the use of a randomized, prospective design, but measure of only one outcome (median pain score by VAS) is one of the limitations. Given the conflicting results of the previous studies, more studies are required to better evaluate the efficacy and safety of this topical compound for relieving pain in diabetic peripheral neuropathy.
Conclusion
In sum, this study demonstrates that amitriptyline is effective in managing diabetic neuropathic pain similar to capsaicin cream with less side effects and better patient compliance. Treatment with topical amitriptyline was safe and without significant side effects associated with systemic therapies. Further studies are required to confirm the efficacy and safety of topical amitriptyline as a treatment of PDN.
Acknowledgements
References
-
1.
Garrod K, ScottLaJoie A, McCabe S. Prevention of ulceration and amputation, by neurolysis of peripheral nerves in diabetics with neuropathy and nerve compression: decision tree utility analysis. J. Diabetes Metab. 2014;5:330.
-
2.
Garcia JM, Velasco PP, Cabrerizo L, Pe´rez M, Go´mez VL. Prevalence of distal diabetic polyneuropathy using quantitative sensory methods in a population with diabetes of more than 10 years’ disease duration. Endocrinol. Nutr. 2010;57:414-420. [PubMed ID: 20638348].
-
3.
Kulkantrakorn K, Lorsuwansiri C, Meesawatsom P. 0.025% capsaicingel for the treatment of painful diabetic neuropathy: a randomized, double blind, crossover, placebo-controlled trial. Pain Pract. 2013;13:497-503. [PubMed ID: 23228119].
-
4.
Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care. 2008;31:S255-S61. [PubMed ID: 18227494].
-
5.
Jorge LL, Feres CC, Teles VE. Topical preparations for pain relief: efficacy and patient adherence. J. Pain Res. 2011;4:11-24. [PubMed ID: 21386951].
-
6.
Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br. J. Anaesth. 2011;107:490-502. [PubMed ID: 21852280].
-
7.
Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging. 1995;7:317-328. [PubMed ID: 8535059].
-
8.
Watson CPN. Topical capsaicin as an adjuvant analgesic. J. Pain Symptom Manage. 1994;9:425-433. [PubMed ID: 7822881].
-
9.
Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998;51:1166-1171. [PubMed ID: 9781549].
-
10.
Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin. J. Pain. 2000;16:S49-S55. [PubMed ID: 10870740].
-
11.
Bryson HM, Wilde MI. Amitriptyline, a review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 1996;8:459-476. [PubMed ID: 8736630].
-
12.
Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin. J. Pain. 2008;24:51-55. [PubMed ID: 18180637].
-
13.
Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J. Pain. 2005;6:644-649. [PubMed ID: 16202956].
-
14.
Uzaraga I, Gerbis B, Holwerda E, Gillis D, Wai E. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study. Support Care Cancer. 2012;20:1515-1524. [PubMed ID: 21847539].
-
15.
Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology. 1995;45:1115-1121. [PubMed ID: 7783874].
-
16.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150-154. [PubMed ID: 8458529].
-
17.
Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005;103:140-146. [PubMed ID: 15983466].
-
18.
Rowbothama MC, Golib V, Kunzc NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697-706. [PubMed ID: 15288411].
-
19.
Kopsky DJ, Hesselink JM. High doses of topical amitriptyline in neuropathic pain: two cases and literature review. Pain Pract. 2012;12:148-153. [PubMed ID: 21676162].
-
20.
Gerner P, Kao G, Srinivasa V, Narang S, Wang GK. Topical amitriptyline in healthy volunteers. Reg. Anesth. Pain Med. 2003;28:289-293. [PubMed ID: 12945021].
-
21.
Lynch ME, Clark AJ, Sawynok J. A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin. J. Pain. 2003;19:323-328. [PubMed ID: 12966259].